A Phase I Trial of Sorafenib (CRAF, BRAF, KIT, RET, VEGFR, PDGFR Inhibitor) or Crizotinib (MET, ALK, ROS1 inhibitor) in Combination with Vemurafenib (BRAF Inhibitor) in Patients with Advanced Malignancies

Trial Profile

A Phase I Trial of Sorafenib (CRAF, BRAF, KIT, RET, VEGFR, PDGFR Inhibitor) or Crizotinib (MET, ALK, ROS1 inhibitor) in Combination with Vemurafenib (BRAF Inhibitor) in Patients with Advanced Malignancies

Recruiting
Phase of Trial: Phase I

Latest Information Update: 03 Apr 2017

At a glance

  • Drugs Crizotinib (Primary) ; Sorafenib (Primary) ; Vemurafenib (Primary)
  • Indications Cancer; Cancer metastases
  • Focus Adverse reactions
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 27 Mar 2017 Planned primary completion date changed from 1 Feb 2018 to 1 Feb 2019.
    • 17 May 2016 Planned primary completion date changed from 1 Feb 2016 to 1 Feb 2018, as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top